Results 121 to 130 of about 10,848 (199)

Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025.

PLoS ONE
BackgroundObinutuzumab is the first glycosylated type II anti-CD20 monoclonal antibody for the treatment of lymphocytic leukemia and follicular lymphoma.
Xiangpeng Li, Haonan Liang, Ping Leng, Zhanqi Cao   +3 more
doaj   +1 more source

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source

Obinutuzumab and Chemotherapy for Front-Line Treatment of Follicular Lymphoma Grade 3B and Composite Follicular Lymphoma: A Study of the Croatian Cooperative Group for Hematologic Diseases (KroHem). [PDF]

Pharmaceuticals (Basel)
Galusic D, Zivkovic N, Basic-Kinda S, Dreta B, Ivic M, Dujmovic D, Moric-Peric M, Holik H, Franjic N, Sincic-Petricevic J, Hude-Dragicevic I, Aurer I.   +11 more
europepmc   +1 more source

Switching Beyond Rituximab in Primary Glomerular Diseases: A Systematic Review of Within-Patient Efficacy and Safety of Non-Rituximab Anti-CD20 Antibodies. [PDF]

Antibodies (Basel)
Martino FK, Stefanelli LF, Cattarin L, Del Prete D, Basso A, Nalesso F.   +5 more
europepmc   +1 more source

Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature. [PDF]

Cureus
Shan HY.
europepmc   +1 more source

Successful treatment of rituximab-refractory pemphigus vulgaris with Obinutuzumab. [PDF]

An Bras Dermatol
Saraç MT, Aygün Alizada M, Erol Mart HM, Boyvat A, Şanlı H, Öktem A.   +5 more
europepmc   +1 more source

Extragenital <i>Mycoplasma hominis</i> infection following obinutuzumab therapy in a patient with chronic lymphocytic leukemia. [PDF]

IDCases
Benandi K, Blanton LS.
europepmc   +1 more source

Subacute immune-mediated thrombotic thrombocytopenic purpura: prolonged prodromes and delayed diagnosis in 5 cases. [PDF]

Res Pract Thromb Haemost
Tehrani TG, Sutton DJ, Whitmill R, Aquil M, Shenouda A, Razzak A, Ahmad H, Saeed M, Lowe GC, Nicolson PLR.   +9 more
europepmc   +1 more source

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. [PDF]

Nat Med
Wu L, Gu L, Fan W, Wei M, Dai T, Li X, Xiao L, Li B, Tian DS, Duan R, Li X, Xu Y, Meng H, Chen T, Gao F, Zhai F, Feng J, Yang H, Zhu R, Zhang CJ, Meng Q, Deng B, Meng Z, Qiu F, Zhou H, Qiu W, Zhang Q, Liu H, Wu Z, Wang Z, Meng L, Li Z, Zang W, Xiang F, Liang J, Liu S, Liu X, Chen J, Li F, Huang D, BeInmost Study Group.   +40 more
europepmc   +1 more source

Treatment of Cold Agglutinin Syndrome Secondary to Chronic Lymphocytic Leukemia With Sutimlimab and Obinutuzumab-Venetoclax. [PDF]

Case Rep Hematol
Lap CJ, Broome CM.
europepmc   +1 more source